MX390082B - Derivados de adenina como inhibidores de proteína quinasa - Google Patents
Derivados de adenina como inhibidores de proteína quinasaInfo
- Publication number
- MX390082B MX390082B MX2018013325A MX2018013325A MX390082B MX 390082 B MX390082 B MX 390082B MX 2018013325 A MX2018013325 A MX 2018013325A MX 2018013325 A MX2018013325 A MX 2018013325A MX 390082 B MX390082 B MX 390082B
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- protein kinase
- pharmaceutically acceptable
- formula
- diseases
- Prior art date
Links
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical class NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 title 1
- 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 title 1
- 239000003909 protein kinase inhibitor Substances 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 4
- 102000001253 Protein Kinase Human genes 0.000 abstract 3
- 108060006633 protein kinase Proteins 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 239000012453 solvate Substances 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 150000001204 N-oxides Chemical class 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010070834 Sensitisation Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000000893 fibroproliferative effect Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 229940043355 kinase inhibitor Drugs 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 abstract 1
- 230000008313 sensitization Effects 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
La presente invención se refiere a un compuesto adecuado para usarse como un inhibidor de cinasa de conformidad con la fórmula general (I) [compuesto (C), en lo sucesivo], o el N-óxido, sal farmacéuticamente aceptable, solvato farmacéuticamente aceptable, o estereoisómero del mismo, fórmula (I) en donde A, R1, R2, R3, R3', R4, R4', X, Y, Z, T son como se define en las reivindicaciones; la invención además se refiere a un método in vitro para inhibir actividad de proteína cinasa que comprende poner en contacto una proteína cinasa con un compuesto de la fórmula (I), o el N-óxido, sal farmacéuticamente aceptable, solvato farmacéuticamente aceptable, o estereoisómero del mismo; la invención además se refiere a los compuestos de la fórmula (I) por sí mismos, así como a su uso como un medicamente, y para usarse o en un método de tratamiento de una enfermedad mediada por una proteína cinasa seleccionada de cáncer, trastornos inflamatorios, enfermedades cardiovasculares, enfermedades inducidas virales, enfermedades circulatorias, enfermedades fibro-proliferativas y trastornos de sensibilización al dolor. (ver fórmula I)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305530 | 2016-05-04 | ||
| PCT/EP2017/060730 WO2017191297A1 (en) | 2016-05-04 | 2017-05-04 | Adenine derivatives as protein kinase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2018013325A MX2018013325A (es) | 2019-08-16 |
| MX390082B true MX390082B (es) | 2025-03-20 |
Family
ID=55953089
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2018013325A MX390082B (es) | 2016-05-04 | 2017-05-04 | Derivados de adenina como inhibidores de proteína quinasa |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11236093B2 (es) |
| EP (1) | EP3452477B1 (es) |
| JP (1) | JP7485502B2 (es) |
| KR (1) | KR102479746B1 (es) |
| CN (1) | CN109311882B (es) |
| AU (1) | AU2017260298B9 (es) |
| EA (1) | EA201892460A1 (es) |
| IL (1) | IL262700B (es) |
| MX (1) | MX390082B (es) |
| SG (1) | SG11201809674QA (es) |
| WO (1) | WO2017191297A1 (es) |
| ZA (1) | ZA201808014B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6920411B2 (ja) * | 2016-07-25 | 2021-08-18 | ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ | コリンキナーゼ阻害剤としてのプリン及び３−デアザプリンアナログ |
| WO2018229197A1 (en) * | 2017-06-14 | 2018-12-20 | European Molecular Biology Laboratory | Bicyclic heteroaromatic urea or carbamate compounds for use in therapy |
| US12303515B2 (en) * | 2019-04-30 | 2025-05-20 | City University Of Hong Kong | PIM1 inhibitors for use in treatment of viral infection and pharmaceutical compositions thereof |
| JP7371221B2 (ja) * | 2019-07-26 | 2023-10-30 | 珠海宇繁生物科技有限責任公司 | Ｉｒａｋ４キナーゼ阻害剤及びその調製方法 |
| CN111560389B (zh) * | 2020-06-11 | 2022-07-01 | 云南中烟工业有限责任公司 | 烟草丝裂原活化蛋白激酶基因NtMAPK8及其应用 |
| JP7728367B2 (ja) | 2021-06-14 | 2025-08-22 | スコーピオン・セラピューティクス・インコーポレイテッド | がんを処置するために使用され得る尿素誘導体 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9010404D0 (en) * | 1990-05-09 | 1990-06-27 | Pfizer Ltd | Therapeutic agents |
| FR2686084B1 (fr) * | 1992-01-10 | 1995-12-22 | Bioprojet Soc Civ | Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques. |
| US6110923A (en) * | 1994-06-22 | 2000-08-29 | Biochem Pharma Inc. | Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity |
| US6713474B2 (en) * | 1998-09-18 | 2004-03-30 | Abbott Gmbh & Co. Kg | Pyrrolopyrimidines as therapeutic agents |
| US6258793B1 (en) * | 1999-12-03 | 2001-07-10 | Cv Therapeutics, Inc. | N6 heterocyclic 5′ modified adenosine derivatives |
| AU2002951247A0 (en) * | 2002-09-06 | 2002-09-19 | Alchemia Limited | Compounds that interact with kinases |
| WO2005009348A2 (en) * | 2003-06-25 | 2005-02-03 | Ariad Pharmaceuticals, Inc. | Substituted purine derivatives |
| WO2005117882A2 (en) * | 2004-04-20 | 2005-12-15 | Incyte Corporation | Hydroxamic acid derivatives as metalloprotease inhibitors |
| EP2532667A1 (en) | 2005-09-30 | 2012-12-12 | Vertex Pharmaceuticals Incorporated | Deazapurines useful as inhibitors of janus kinases |
| US20070238746A1 (en) * | 2006-04-06 | 2007-10-11 | Trixi Brandl | Thiazolyl-dihydro-chinazoline |
| TWI444384B (zh) * | 2008-02-20 | 2014-07-11 | Gilead Sciences Inc | 核苷酸類似物及其在治療惡性腫瘤上的用途 |
| US20120034250A1 (en) | 2009-04-14 | 2012-02-09 | Astellas Pharma Inc. | Condensed pyrrolopyridine derivative |
| EP2508607A1 (en) | 2011-04-07 | 2012-10-10 | Helmholtz-Zentrum für Infektionsforschung GmbH | Medicament for liver regeneration and for treatment of liver failure |
| SG11201503893RA (en) * | 2012-11-19 | 2015-06-29 | Agency Science Tech & Res | Method of treating cancer |
| WO2014141129A2 (en) * | 2013-03-14 | 2014-09-18 | Grueneberg Dorre A | Novel methods, compounds, and compositions for inhibition of ros |
-
2017
- 2017-05-04 EP EP17722013.4A patent/EP3452477B1/en active Active
- 2017-05-04 EA EA201892460A patent/EA201892460A1/ru unknown
- 2017-05-04 MX MX2018013325A patent/MX390082B/es unknown
- 2017-05-04 JP JP2018557916A patent/JP7485502B2/ja active Active
- 2017-05-04 WO PCT/EP2017/060730 patent/WO2017191297A1/en not_active Ceased
- 2017-05-04 KR KR1020187034306A patent/KR102479746B1/ko active Active
- 2017-05-04 AU AU2017260298A patent/AU2017260298B9/en active Active
- 2017-05-04 CN CN201780033173.5A patent/CN109311882B/zh active Active
- 2017-05-04 US US16/097,805 patent/US11236093B2/en active Active
- 2017-05-04 SG SG11201809674QA patent/SG11201809674QA/en unknown
-
2018
- 2018-10-31 IL IL262700A patent/IL262700B/en unknown
- 2018-11-27 ZA ZA2018/08014A patent/ZA201808014B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017260298B2 (en) | 2021-09-02 |
| EP3452477B1 (en) | 2023-09-13 |
| NZ748751A (en) | 2024-12-20 |
| CN109311882B (zh) | 2022-02-11 |
| WO2017191297A1 (en) | 2017-11-09 |
| JP2019516688A (ja) | 2019-06-20 |
| US11236093B2 (en) | 2022-02-01 |
| US20190127379A1 (en) | 2019-05-02 |
| KR20190003968A (ko) | 2019-01-10 |
| AU2017260298B9 (en) | 2021-09-30 |
| CN109311882A (zh) | 2019-02-05 |
| IL262700A (en) | 2018-12-31 |
| JP7485502B2 (ja) | 2024-05-16 |
| BR112018072468A2 (pt) | 2019-02-19 |
| SG11201809674QA (en) | 2018-11-29 |
| KR102479746B1 (ko) | 2022-12-21 |
| AU2017260298A1 (en) | 2018-12-13 |
| CA3022896A1 (en) | 2017-11-09 |
| EP3452477A1 (en) | 2019-03-13 |
| ZA201808014B (en) | 2020-02-26 |
| MX2018013325A (es) | 2019-08-16 |
| EP3452477C0 (en) | 2023-09-13 |
| EA201892460A1 (ru) | 2019-09-30 |
| IL262700B (en) | 2022-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20200315A1 (ar) | مركبات بورينون واستخدامها في معالجة السرطان | |
| MX390082B (es) | Derivados de adenina como inhibidores de proteína quinasa | |
| PH12020551332A1 (en) | Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors | |
| PH12020550503A1 (en) | Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors | |
| MX387394B (es) | Compuestos heterociclicos como inhibidores de la cinasa ret. | |
| MX2020007265A (es) | Derivados de rapamicina. | |
| MX386089B (es) | Compuesto heterociclico utilizado como inhibidor de fgfr. | |
| EA201991693A1 (ru) | Производное пиридина в качестве ингибитора ask1 и способ его получения и применения | |
| PH12019501350B1 (en) | Amino-triazolopyridine compounds and their use in treating cancer | |
| MX2024009886A (es) | Derivados de quinolina como inhibidores de integrina alfa4beta7. | |
| MX387443B (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| MX393057B (es) | Compuestos de indol carboxamida útiles como inhibidores de cinasas. | |
| EA201992126A1 (ru) | Ингибиторы jak, содержащие 4-членный гетероциклический амид | |
| EA201790122A1 (ru) | Производные 2-h-индазола в качестве ингибиторов циклинзависимых киназ (cdk) и их терапевтическое применение | |
| CA2925624C (en) | Substituted nicotinimide inhibitors of btk and their preparation and use in the treatment of cancer, inflammation and autoimmune disease | |
| WO2015200481A8 (en) | Mnk inhibitors and methods related thereto | |
| EA201891091A1 (ru) | Соединения ингибитора jak киназы для лечения респираторного заболевания | |
| EA201171454A1 (ru) | N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ | |
| EA201691428A1 (ru) | Бициклические гетероциклические производные в качестве ингибиторов irak4 | |
| MX391410B (es) | Derivados de quinolino-pirrolidin-2-ona como inhibidores del gen mutado de ataxia telangiectasia (atm) y el uso de los mismos en el tratamiento de tumores sólidos. | |
| EA201070929A1 (ru) | ФУРО- И ТИЕНО[3,2-c]ПИРИДИНЫ | |
| MX381994B (es) | Inhibidor de janus quinasa. | |
| PH12022550470A1 (en) | Triazolopyrimidines as a2a / a2b inhibitors | |
| WO2014194245A3 (en) | Cdk8 inhibitors and uses thereof | |
| EA201991355A1 (ru) | Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта |